Serious adverse events – measured by self‐report and medical records · people who smoke
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
It is very uncertain whether heated tobacco use changes serious adverse events – measured by self‐report and medical records compared with cigarette smoking (very low certainty).
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
1 finding from 1 review
Serious adverse events at 1 week to 1 year Assessed via self‐report and medical records · People who smoke cigarettes
Nicotine EC showed no clear difference in serious adverse events at 1 week to 1 year Assessed via self‐report… compared with non‐nicotine EC (low certainty).
1 finding from 1 review
Serious adverse events at 4 weeks to 1 year Assessed via self‐report and medical records · people who smoke
Nicotine EC showed no clear difference in serious adverse events at 4 weeks to 1 year Assessed via self‐report… compared with NRT (low certainty).
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
It is very uncertain whether nicotine EC changes serious adverse events at 4 weeks to 8 months Assessed via… compared with behavioural support only/no support (very low certainty).
1 finding from 1 review
Adverse events (serious and nonserious) Medical Dictionary for Regulatory Activities (MedDRA) · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab showed no clear difference in adverse events (serious and nonserious) Medical Dictionary for… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with gastro‐oesophageal reflux disease (GORD) in adults
It is very uncertain whether laparoscopic fundoplication changes serious adverse events compared with medical management (very low certainty).
1 finding from 1 review
Secondary outcome:total serious adverse events at the end of · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome:total serious adverse events at the end of compared with medical therapy (low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Serious adverse events (at 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab changes serious adverse events (at 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review